€485.50
0.51% today
Brüssel, Sep 16, 05:35 pm CET
ISIN
NL0010832176
Symbol
ARGX
Sector
Industry

arGEN-X Stock price

€485.50
+7.90 1.65% 1M
+152.30 45.71% 6M
+142.00 41.34% YTD
-2.70 0.55% 1Y
+212.80 78.03% 3Y
+369.70 319.26% 5Y
+477.19 5,742.36% 10Y
Brüssel, Closing price Mon, Sep 16 2024
-2.50 0.51%
ISIN
NL0010832176
Symbol
ARGX
Sector
Industry

Key metrics

Market capitalization €29.18b
Enterprise Value €26.32b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 17.62
P/S ratio (TTM) P/S ratio 19.53
P/B ratio (TTM) P/B ratio 7.34
Revenue growth (TTM) Revenue growth 96.25%
Revenue (TTM) Revenue €1.49b
EBIT (operating result TTM) EBIT €-366.78m
Free Cash Flow (TTM) Free Cash Flow €-135.49m
EPS (TTM) EPS €-3.23
P/E forward negative
P/S forward 15.88
EV/Sales forward 14.32
Show more

Is arGEN-X a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.

arGEN-X Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a arGEN-X forecast:

26x Buy
84%
5x Hold
16%

Analyst Opinions

31 Analysts have issued a arGEN-X forecast:

Buy
84%
Hold
16%

Financial data from arGEN-X

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '23
+/-
%
1,134 1,134
190% 190%
100%
- Direct Costs 209 209
64% 64%
18%
926 926
251% 251%
82%
- Selling and Administrative Expenses 542 542
60% 60%
48%
- Research and Development Expense 697 697
31% 31%
61%
-314 -314
49% 49%
-28%
- Depreciation and Amortization 103 103
4% 4%
9%
EBIT (Operating Income) EBIT -417 -417
41% 41%
-37%
Net Profit -273 -273
60% 60%
-24%

In millions EUR.

Don't miss a Thing! We will send you all news about arGEN-X directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.

Head office Netherlands
CEO Tim Hauwermeiren
Employees 1,148
Founded 2008
Website www.argen-x.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today